The coronavirus disease 2019 (COVID-19) pandemic has exposed and further exacerbated the fractures in our healthcare and social delivery systems.
There has never been a more urgent time for manufacturers to develop or evolve their strategic frameworks to address adverse social risk factors that have been exacerbated by the COVID-19 pandemic and contribute to health inequities glaringly evident during the pandemic. This article describes strategies pharmaceutical manufacturers must adopt to address social determinants of health and population health management challenges, supporting patients, families, and clinicians during this pandemic and beyond.
Read the full article here!
